Table 1
Clinical characteristics, therapy regimens, and outcomes for the patients with K. ohmeri fungemia in Korea

Sex /age	Underlying conditions	No. of blood culture (day) positive for K. ohmeri	Immunosuppressive status	Vascular catheter or IP	Antifungal therapy	Outcome	Reference
M/59	V-P shunt	4(0, 6, 8, 13)	No	VP shunt	Amp-B	RC	14
	infection
M/11	Burkitt’s	4(0, 12, 13. 14)	Yes(chemotherapy)	CVC	FC	Exitus	14
	lymphoma
M/41	Alcoholic KA,	3(0, 5, 7)	No	CVC	None	RC	14
	Tuberculosis
M/47	DM, CRF	10(0-5, 8,9,11,12)	No	CVC	Amp-B	Exitus	14
F/4	TOF, fungemia	1	Yes(immunotherapy)	CVC	Amp-B	Exitus	14
F/0	Prematurity	1	Yes(prematurity)	UAVC	None	RC	14
	with VLBW
F/73	Colon cancer	1	Yes(chemotherapy)	No*	FC →	RC	15
					Amp-B
M/70	GI cancer	1	Yes(chemotherapy)	No†	FC	RC	Present
							study

Abbreviations: V-P, ventriculoperitoneal; KA, ketoacidosis; DM, diabetes mellitus; CRF, chronic renal failure; TOF, tetralogy of Fallot; VLBW, very low birth weight; GI, gastrointestinal; IP, invasive procedure; CVC, central venous catheter; UAVC, umbilical artery and vein catheter; Amp-B, amphotericin-B, FC, fluconazole; RC, recovered.
After receiving stent insertion with colonoscopy* or a biliary stent insertion with ERCP†.